{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:05Z","timestamp":1790840405279,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The diffuse large B-cell lymphoma (DLBCL) has the highest incidence of all lymphomas worldwide. To investigate the functions of lymphocyte activation gene 3 (LAG-3) and programmed cell death 1 (PD-1) in tissues and peripheral blood of patients with DLBCL, the expression of LAG-3 and PD-1 genes in DLBCL-TCGA were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>LAG-3<\/jats:italic>\n                      and\n                      <jats:italic>PD-1<\/jats:italic>\n                      mRNA levels in DLBCL were analyzed using data from The Cancer Genome Atlas (TCGA) database. Utilize the Genotype-Tissue Expression (GTEx) database for assessing the variance in the expression of LAG-3, PD-1, and other associated factors between the tissues of DLBCL patients and healthy individuals. Immunohistochemistry was applied to detect the expression of LAG-3 and PD-1 levels in 137 cases of DLBCL tissues and 20 cases of reactive lymphoid hyperplasia. The prognostic value of LAG-3 and PD-1 were assessed using the Kaplan-Meier curve. The Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) and ssGSEA algorithm were used to explore the immune microenvironment of DLBCL. Additionally, the expression and co-expression of LAG-3 and PD-1 were detected on CD4 and CD8 T cells in peripheral blood samples from 100 cases of DLBCL tissues and 30 cases of healthy individuals using flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to TCGA database,\n                      <jats:italic>LAG-3<\/jats:italic>\n                      and\n                      <jats:italic>PD-1<\/jats:italic>\n                      gene expression levels were significantly up-regulated in DLBCL tissues. LAG-3 and PD-1 levels were also strongly positively correlated with those of most infiltrating immune cells. Overall survival of patients with high\n                      <jats:italic>LAG-3<\/jats:italic>\n                      and\n                      <jats:italic>PD-1<\/jats:italic>\n                      co-expression was significantly shorter than that of patients with low co-expression. In DLBCL patients, LAG-3 and PD-1 were highly expressed in peripheral blood CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. In addition, LAG-3 was highly expressed in CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, while the expression of PD-1 in CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells of DLBCL patients showed no significant difference compared to healthy individuals. Additionally, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and SU-DHL6\/OCI-LY3 from patients with DLBCL were co-cultured\n                      <jats:italic>in vitro<\/jats:italic>\n                      ; after addition of LAG-3 and\/or PD-1 inhibitors alone, an increased perforin and granzyme B secretion levels by CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were detected, as well as an increase in the overall proportion of tumor cells undergoing apoptosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      High LAG-3 and PD-1 levels significantly inhibit CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell function, resulting in weakened ability to kill tumor cells. Combined LAG-3 and PD-1 blockade can restore CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell function and provides a potential avenue for development of personalized cellular immunotherapy for DLBCL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1265255","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:01:11Z","timestamp":1695906071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiajia","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.22","article-title":"Erratum: Germline mutations predisposing to diffuse large B-cell lymphoma","volume":"7","author":"Leeksma","year":"2017","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41408-019-0208-6","article-title":"Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma","volume":"9","author":"Nowakowski","year":"2019","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21690731.2016.1220899","article-title":"The eukaryotic translation initiation factor eIF4E wears a \u201ccap\u201d for many occasions","volume":"4","author":"Borden","year":"2016","journal-title":"Translation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2019002395","article-title":"Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier","volume":"135","author":"Carpio","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"JCO"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2847","article-title":"Validation of melanoma immune profile (MIP), a prognostic immune gene prediction score for stage II\u2013III melanoma","volume":"25","author":"Gartrell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107722","article-title":"Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis","volume":"96","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00999","article-title":"Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity","volume":"10","author":"Seliger","year":"2019","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578349","article-title":"Leveraging endogenous dendritic cells to enhance the therapeutic efficacy of adoptive T-cell therapy and checkpoint blockade","volume":"11","author":"H\u00fcbbe","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","article-title":"The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms","volume":"184","author":"Vardiman","year":"2010","journal-title":"Chemico-Biological Interact"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","article-title":"Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets","volume":"8","author":"Nagy","year":"2018","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.19852\/j.cnki.jtcm.20201208.001","article-title":"Network pharmacology assessment of Qingkailing injection treatment of cholestatic hepatitis","volume":"41","author":"Lian","year":"2021","journal-title":"J Tradit Chin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S350109","article-title":"Microglia-mediated neuroinflammation: A potential target for the treatment of cardiovascular diseases","volume":"15","author":"Wang","year":"2022","journal-title":"JIR"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1806191","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"379","author":"Kikkeri","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging opportunities and challenges in cancer immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2017.01.012","article-title":"The NLRP3 inflammasome modulates sleep and NREM sleep delta power induced by spontaneous wakefulness, sleep deprivation and lipopolysaccharide","volume":"62","author":"Zielinski","year":"2017","journal-title":"Brain Behavior Immun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"JCO"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"JCO"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.794217","article-title":"Case report: sarcoid-like reactions and tertiary lymphoid structures following dual checkpoint inhibition in a patient with early-stage lung adenocarcinoma","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1265255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:01:17Z","timestamp":1695906077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1265255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2023.1265255"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1265255","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"article-number":"1265255"}}